Asthma, Allergy & Lung Biology (AALB) (Research Division)
PhD
In London
Description
-
Type
PhD
-
Location
London
Overview
REF2014: Ranked first in the United Kingdom for Clinical Medicine, in terms of the proportion of our overall submission that was ranked 4* or 3* (Unit of Assessment 1 – Clinical Medicine).
Research income: £23m over the last five years.
Current number of academic staff: 38 faculty members.
Current number of research students: MPhil/PhD 43; MD 13.
Recent publications
Enhanced production of IL-17A in patients with severe asthma is inhibited by 1α,25-dihydroxyvitamin D3 in a glucocorticoid-independent fashion.
Conformational changes in IgE contribute to its uniquely slow dissociation rate from receptor FcɛRI.
Human T(H)2 cells respond to cysteinyl leukotrienes through selective expression of cysteinyl leukotriene receptor 1.
Identifying infants at high risk of peanut allergy: the Learning Early About Peanut Allergy (LEAP) screening study.
Rhinovirus infection and healthcare utilisation in prematurely born infants.
Current research projects
Prevention of Allergy, Asthma & Chronic Respiratory Morbidity;
IgE Structure, Function & Regulation;
Immune Mechanisms of Asthma (Cellular/Molecular);
Therapy including Immunomodulation;
Respiratory Physiology and Airways Remodelling;
Adult Clinical Respiratory Physiology;
Paediatric Clinical Respiratory Physiology;
Lung Cancer;
Environmental Impact of Respiratory Health (Pollution, Vitamin D).
Epigenetic regulation of gene expression
Partner organisations
Department of Respiratory Medicine & Allergy;
Department of Paediatrics, Department of Paediatric Allergy;
Randall Division of Cell & Molecular Biophysics;
MRC & Asthma UK Centre in Allergic Mechanisms of Asthma.
Facilities
Location
Start date
Start date
Reviews
Subjects
- Allergy
- Biology
- Physiology
- Healthcare
Course programme
The Division of Asthma, Allergy & Lung Biology has three main research aims:
- To elucidate the basic mechanisms that underlie the causes and effects of airway inflammation
- To understand mechanisms of anti-inflammatory drug action
- To find ways to improve hospital care for very ill patients, including those with respiratory failure.
Our research programmes range from basic science to clinical research and include studies that will elucidate the molecular and physiological mechanisms of inflammation; research to identify and test new therapeutic approaches to treating allergies, inflammation and cancer; and clinical trials to test new allergy prevention strategies.
We have a critical research mass within the Division that creates unique synergies and offers opportunities for researchers to work closely and productively while preserving scientific independence. The close interface between our clinical and lab-based research is one of the keys to our success. We share knowledge, equipment, reagents and human materials (such as biopsy material, cell lines and clones) to maximise the potential of our resources and help translate advances in our understanding of allergic and respiratory diseases into healthcare benefits for patients as rapidly as possible.
Our research strategy is to understand the molecular, immunological and physiological mechanisms of asthma, allergy and related respiratory diseases, including COPD and lung cancer; to identify new therapeutic targets; to test new treatment strategies and to find ways to improve hospital care for adults and children with severe lung diseases including respiratory failure.
Asthma, Allergy & Lung Biology (AALB) (Research Division)